Birth Control Patch Study
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
173
0.55 mg ethinyl estradiol \& 2.1 mg gestodene, 21 days for 3 cycles
Unnamed facility
Tucson, Arizona, United States
Unnamed facility
San Diego, California, United States
Unnamed facility
Sandy Springs, Georgia, United States
Unnamed facility
Philadelphia, Pennsylvania, United States
Determination of Hoogland Scores
Time frame: Treatment Cycles 2 & 3
Laboratory values for E2, progesterone, FSH and LH
Time frame: Pretreatment & regularly during Treatment Cycles 1, 2, 3
Endometrial thickness
Time frame: Pretreatment & regularly during Treatment Cycles 1, 2, 3
Follicle size
Time frame: Pretreatment & regularly during Treatment Cycles 1, 2, 3
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Houston, Texas, United States
Unnamed facility
Seattle, Washington, United States